We will examine the risk of heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF risk reduction in patients with T2D and CV disease or multiple CV risk factors. We’ll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.Presenter: Serge Jabbour, MD, FACP, FACEProfessor of MedicineDirector, Division of Endocrinology, Diabetes & Metabolic DiseaseSidney Kimmel Medical College at Thomas Jefferson UniversityPhiladelphia, PA